Survival at 8 weeks after diagnosis-based antituberculosis treatment was better with urine-based lipoarabinomannan (LAM) testing than with routine testing.
Tuberculosis remains the leading cause of death in patients who are coinfected with HIV. Immunocompromised patients may have extrapulmonary or paucibacillary tuberculosis, which makes diagnosis with the current routine diagnostic tests challenging. To test the effect of a urine-based tuberculosis test on mortality in HIV coinfected patients, researchers conducted a clinical trial in 2528 HIV-positive hospitalized patients in South Africa, Tanzania, Zambia, and Zimbabwe who were randomized to usual testing (smear microscopy, Xpert-MTB/RIF, and sputum culture) with or without a rapid, low-cost, urine-based point-of-care Alere Determine TB lipoarabinomannan (LAM) Ag test assay, followed by antituberculosis treatment in patients who tested posi…
Reviewing Author
DisclosuresConsultant/Advisory BoardUNAIDS; WHO; Bill and Melinda Gates Foundation, Population Council
Grant/Research SupportNIH; National Institute of Allergy and Infectious Diseases; Tides Foundation/MAC AIDS Fund; USAID; South African National Research Foundation; European Union; South African Medical Research Council
Editorial BoardsNew England Journal of Medicine; AIDS Reviews; AIDS Research and Human Retroviruses; mBio; Indian Journal of Medical Research; JAIDS: Journal of Acquired Immune Deficiency Syndromes
DisclosuresConsultant/Advisory BoardUNAIDS; WHO; Bill and Melinda Gates Foundation, Population Council
Grant/Research SupportNIH; National Institute of Allergy and Infectious Diseases; Tides Foundation/MAC AIDS Fund; USAID; South African National Research Foundation; European Union; South African Medical Research Council
Editorial BoardsNew England Journal of Medicine; AIDS Reviews; AIDS Research and Human Retroviruses; mBio; Indian Journal of Medical Research; JAIDS: Journal of Acquired Immune Deficiency Syndromes